# Pramlintide as an adjunct to insulin therapy.

> PubMed lists PMID 12685439 in Current diabetes reports as Comment, Journal Article, with publication-date metadata of 2003-02 (month precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-12685439-pramlintide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-12685439-pramlintide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-12685439-pramlintide-v1.json
- Content SHA-256: `901e9d5dea5520741bda36121942db71e9ccce5d9ee03e85ba5e7854686d0465`

## Claims and source pins

### Headline

Pramlintide as an adjunct to insulin therapy. ([`pubmed-observation-pmid-12685439-2019-11-07-0ccb5ce04285`](#source-pubmed-observation-pmid-12685439-2019-11-07-0ccb5ce04285))

### Summary

PubMed lists PMID 12685439 in Current diabetes reports as Comment, Journal Article, with publication-date metadata of 2003-02 (month precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12685439-2019-11-07-0ccb5ce04285`](#source-pubmed-observation-pmid-12685439-2019-11-07-0ccb5ce04285))

### Paragraph 1

PubMed lists PMID 12685439 in Current diabetes reports as Comment, Journal Article, with publication-date metadata of 2003-02 (month precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12685439-2019-11-07-0ccb5ce04285`](#source-pubmed-observation-pmid-12685439-2019-11-07-0ccb5ce04285))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-12685439-2019-11-07-0ccb5ce04285`](#source-pubmed-observation-pmid-12685439-2019-11-07-0ccb5ce04285))

## Sources

<a id="source-pubmed-observation-pmid-12685439-2019-11-07-0ccb5ce04285"></a>
- **Pramlintide as an adjunct to insulin therapy. · retained source version 1:2019-11-07:current:0ccb5ce04285642b3a517ba52c82c1d780d4029127a06cb7dc7e5f0e760806a6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/12685439/) (`pubmed-observation-pmid-12685439-2019-11-07-0ccb5ce04285`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Pramlintide as an adjunct to insulin therapy." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-12685439-pramlintide-v1.json SHA-256: 901e9d5dea5520741bda36121942db71e9ccce5d9ee03e85ba5e7854686d0465.